Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Have you heard the big news? Bill Gates, co-chair of the Bill & Melinda Gates Foundation and Founder of Breakthrough Energy, will be speaking at GreenBiz 21 — the premier annual event for business leaders!
Gates joins a dynamic speaker lineup of nearly 200 thought leaders and will kick off GreenBiz 21 with his session “How to Avoid a Climate Disaster: The Critical Role Businesses Must Play” on February 9.
September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide.
Researchers at three institutions in the U.S. and U.K. receive grants to advance studies of repurposed drugs and novel antibodies in preventing COVID-19
Press Release
PURCHASE, NY – March 31, 2020 /3BL Media/ – The partners in the COVID-19 Therapeutics Accelerator have announced grants of $20 million to three institutions—the University of Washington, University of Oxford, and La Jolla Institute for Immunology—to fund clinical trials in order to identify highly potent immunotherapies for the COVID-19 pandemic.
Collaboration to address product development and scale up challenges posed by current pandemic
Press Release
BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide.
There is a lot of COVID-19 information out there, so here’s a guide to help combat the “infodemic”.
Summary:
Why Global Citizens should care:
The response to the coronavirus pandemic is threatened by misinformation, putting the health of individuals and the public at greater risk — for example, through the sharing of unsubstantiated medical advice. We can all play a part in limiting the spread of dangerous misinformation, through ensuring we only use reliable resources, and don't share fake news on. You can join our Together At Home campaign against coronavirus by taking action here.
Blog
Why Global Citizens should care:
The response to the coronavirus pandemic is threatened by misinformation, putting the health of individuals and the public at greater risk — for example, through the sharing of unsubstantiated medical advice. We can all play a part in limiting the spread of dangerous misinformation, through ensuring we only use reliable resources, and don't share fake news on. You can join our Together At Home campaign against coronavirus by taking action here.
When Dr. Charles A. Knirsch, MD, MPH, joined Pfizer more than 20 years ago, planning had just begun for a new partnership to eliminate trachoma, a neglected tropical disease and the world’s leading infectious cause of blindness.
The New England Journal of Medicine has published results from a new study showing that the use of an antibiotic significantly reduced mortality among children living in three low-income countries in Sub-Saharan Africa.
November 21, 2014 /3BL Media/ - For more than two years, Kohler Co., global leader in kitchen and bath design and technology, has collaborated with Caltech in the development of a photovoltaic toilet as part of the Reinvent the Toilet Challenge, hosted by the Bill & Melinda Gates Foundation.
